Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31330814 | 0.86 | GPR119 (0.55) | ALDH1A1MAPTMEN1KMT2AUSP2 | |
| SCHEMBL28885236 | 0.83 | MAPT (0.54) | ALDH1A1HPGDALOX15HSD17B10NPC1 | |
| SCHEMBL26139475 | 0.83 | USP2 (0.60) | ALDH1A1HPGDALOX15HSD17B10NPC1 | |
| SCHEMBL23460117 | 0.81 | HRH3 (0.54) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL29931204 | 0.81 | HRH3 (0.54) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL27175805 | 0.80 | USP30 (0.43) | ALDH1A1HPGDALOX15HSD17B10NPC1 | |
| SCHEMBL15070420 | 0.80 | USP2 (0.69) | ALDH1A1HPGDALOX15MGLLHSD17B10 | |
| SCHEMBL1097622 | 0.80 | ALDH1A1 (0.63) | ALDH1A1HPGDALOX15MGLLHSD17B10 | |
| SCHEMBL1063179 | 0.79 | ALDH1A1 (0.67) | ALDH1A1HPGDALOX15MGLLHSD17B10 | |
| SCHEMBL17557647 | 0.79 | ALDH1A1 (0.61) | ALDH1A1HPGDALOX15MGLLHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142629-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230142629-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| EP-4107158-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | Nurix Therapeutics, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| CN-115335381-A | Bifunctional degradants of interleukin-1 receptor-associated kinase and therapeutic uses thereof | 新锐思生物制药股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142629-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | IRAK1, IRAK2, IRAK4 | ALDH1A1 1632/4885HPGD 4074/4885ALOX15 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.